The role of the protein tyrosine phosphatase SHP2 in cardiac development and disease

Seminars in Cell and Developmental Biology

Volumn 37, Issue , 2015, Pages 73-81

  Lauriol, Jessica ^a   Jaffré, Fabrice ^a   Kontaridis, Maria I ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiac development; Congenital heart disease; Myocardium; Phosphatase; PTPN11; SHP2

Indexed keywords

COFILIN; ELASTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; VASCULOTROPIN;

ACTIN POLYMERIZATION; CELL COMMUNICATION; ENDOCARDIAL CUSHION; ENDOPLASMIC RETICULUM; ENZYME STRUCTURE; GASTRULATION; GENE MUTATION; HEART DEVELOPMENT; HEART DISEASE; HEART VALVE; HUMAN; NONHUMAN; REVIEW; STEM CELL; ANIMAL; CARDIAC MUSCLE; CELL SURVIVAL; CONGENITAL HEART MALFORMATION; CYTOLOGY; EMBRYOLOGY; GENETICS; HEART; METABOLISM; MUTATION;

ANIMALS; CELL SURVIVAL; HEART; HEART DEFECTS, CONGENITAL; HUMANS; MUTATION; MYOCARDIUM; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; STEM CELLS;

EID: 84924062761     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2014.09.013     Document Type: Review

References (85)

1. Weismann C.G., Gelb B.D. The genetics of congenital heart disease: a review of recent developments. Curr Opin Cardiol 2007, 22(3):200-206.
2. Eisenberg L.M., Markwald R.R. Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circ Res 1995, 77(1):1-6.
3. Hof P., Pluskey S., Dhe-Paganon S., Eck M.J., Shoelson S.E. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998, 92(4):441-450.
4. Barford D., Neel B.G. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 1998, 6(3):249-254.
5. Neel B.G., Gu H., Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003, 28(6):284-293.
6. Feng G.S. Shp-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res 1999, 253(1):47-54.
7. Tonks N.K., Neel B.G. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol 2001, 13(2):182-195.
8. Van Vactor D., O'Reilly A.M., Neel B.G. Genetic analysis of protein tyrosine phosphatases. Curr Opin Genet Dev 1998, 8(1):112-126.
9. Zhang S.Q., Yang W., Kontaridis M.I., Bivona T.G., Wen G., Araki T., et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell 2004, 13(3):341-355.
10. Agazie Y.M., Hayman M.J. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol 2003, 23(21):7875-7886.
11. Hanafusa H., Torii S., Yasunaga T., Matsumoto K., Nishida E. Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. J Biol Chem 2004, 279(22):22992-22995.
12. Zhang S.Q., Tsiaras W.G., Araki T., Wen G., Minichiello L., Klein R., et al. Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2. Mol Cell Biol 2002, 22(12):4062-4072.
13. Lehmann U., Schmitz J., Weissenbach M., Sobota R.M., Hortner M., Friederichs K., et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 2003, 278(1):661-671.
14. You M., Flick L.M., Yu D., Feng G.S. Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor. J Exp Med 2001, 193(1):101-110.
15. Fornaro M., Burch P.M., Yang W., Zhang L., Hamilton C.E., Kim J.H., et al. SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth. J Cell Biol 2006, 175(1):87-97.
16. Kontaridis M.I., Eminaga S., Fornaro M., Zito C.I., Sordella R., Settleman J., et al. SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway. Mol Cell Biol 2004, 24(12):5340-5352.
17. Marino B., Digilio M.C., Toscano A., Giannotti A., Dallapiccola B. Congenital heart diseases in children with Noonan syndrome: an expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr 1999, 135(6):703-706.
18. Yoshida R., Hasegawa T., Hasegawa Y., Nagai T., Kinoshita E., Tanaka Y., et al. Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. J Clin Endocrinol Metab 2004, 89(7):3359-3364.
19. Tartaglia M., Kalidas K., Shaw A., Song X., Musat D.L., van der Burgt I., et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002, 70(6):1555-1563.
20. Nishikawa T., Ishiyama S., Shimojo T., Takeda K., Kasajima T., Momma K. Hypertrophic cardiomyopathy in Noonan syndrome. Acta Paediatr Jpn 1996, 38(1):91-98.
21. Digilio M.C., Marino B., Picchio F., Prandstraller D., Toscano A., Giannotti A., et al. Noonan syndrome and aortic coarctation. Am J Med Genet 1998, 80(2):160-162.
22. Limongelli G., Pacileo G., Marino B., Digilio M.C., Sarkozy A., Elliott P., et al. Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. Am J Cardiol 2007, 100(4):736-741.
23. Martinez-Quintana E., Rodriguez-Gonzalez F. LEOPARD syndrome: clinical features and gene mutations. Mol Syndromol 2012, 3(4):145-157.
24. Keilhack H., David F.S., McGregor M., Cantley L.C., Neel B.G. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 2005, 280(35):30984-30993.
25. Kontaridis M.I., Swanson K.D., David F.S., Barford D., Neel B.G. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 2006, 281(10):6785-6792.
26. Hanna N., Montagner A., Lee W.H., Miteva M., Vidal M., Vidaud M., et al. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett 2006, 580(10):2477-2482.
27. Marin T.M., Keith K., Davies B., Conner D., Guha P., Kalaitzidis D., et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest 2011, 121(3):1026-1043.
28. Yu Z.H., Xu J., Walls C.D., Chen L., Zhang S., Zhang R., et al. Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations. J Biol Chem 2013, 288(15):10472-10482.
29. Qiu W., Wang X., Romanov V., Hutchinson A., Lin A., Ruzanov M., et al. Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11). BMC Struct Biol 2014, 14:10.
30. Yang W., Klaman L.D., Chen B., Araki T., Harada H., Thomas S.M., et al. An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev Cell 2006, 10(3):317-327.
31. Anneren C., Cowan C.A., Melton D.A. The Src family of tyrosine kinases is important for embryonic stem cell self-renewal. J Biol Chem 2004, 279(30):31590-31598.
32. Wu D., Pang Y., Ke Y., Yu J., He Z., Tautz L., et al. A conserved mechanism for control of human and mouse embryonic stem cell pluripotency and differentiation by shp2 tyrosine phosphatase. PLoS One 2009, 4(3):e4914.
33. Dehaan R.L. Migration patterns of the precardiac mesoderm in the early chick embryo. Exp Cell Res 1963, 29:544-560.
34. Warkman A.S., Krieg P.A. Xenopus as a model system for vertebrate heart development. Semin Cell Dev Biol 2007, 18(1):46-53.
35. Buckingham M., Meilhac S., Zaffran S. Building the mammalian heart from two sources of myocardial cells. Nat Rev Genet 2005, 6(11):826-835.
36. Brade T., Pane L.S., Moretti A., Chien K.R., Laugwitz K.L. Embryonic heart progenitors and cardiogenesis. Cold Spring Harb Perspect Med 2013, 3(10):a013847.
37. Langdon Y.G., Goetz S.C., Berg A.E., Swanik J.T., Conlon F.L. SHP-2 is required for the maintenance of cardiac progenitors. Development 2007, 134(22):4119-4130.
38. Tirosh-Finkel L., Zeisel A., Brodt-Ivenshitz M., Shamai A., Yao Z., Seger R., et al. BMP-mediated inhibition of FGF signaling promotes cardiomyocyte differentiation of anterior heart field progenitors. Development 2010, 137(18):2989-3000.
39. Jopling C., van Geemen D., den Hertog J. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects. PLoS Genet 2007, 3(12):e225.
40. Stewart R.A., Sanda T., Widlund H.R., Zhu S., Swanson K.D., Hurley A.D., et al. Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev Cell 2010, 18(5):750-762.
41. van den Berg G., Abu-Issa R., de Boer B.A., Hutson M.R., de Boer P.A., Soufan A.T., et al. A caudal proliferating growth center contributes to both poles of the forming heart tube. Circ Res 2009, 104(2):179-188.
42. Bayraktar M., Manner J. Cardiac looping may be driven by compressive loads resulting from unequal growth of the heart and pericardial cavity. Observations on a physical simulation model. Front Physiol 2014, 5:112.
43. Shi Y., Yao J., Young J.M., Fee J.A., Perucchio R., Taber L.A. Bending and twisting the embryonic heart: a computational model for c-looping based on realistic geometry. Front Physiol 2014, 5:297.
44. Ramasubramanian A., Latacha K.S., Benjamin J.M., Voronov D.A., Ravi A., Taber L.A. Computational model for early cardiac looping. Ann Biomed Eng 2006, 34(8):1655-1669.
45. Manning A., McLachlan J.C. Looping of chick embryo hearts in vitro. J Anat 1990, 168:257-263.
46. Davidson B.P., Tam P.P. The node of the mouse embryo. Curr Biol 2000, 10(17):R617-R619.
47. Tanaka Y., Okada Y., Hirokawa N. FGF-induced vesicular release of Sonic hedgehog and retinoic acid in leftward nodal flow is critical for left-right determination. Nature 2005, 435(7039):172-177.
48. Hirokawa N., Tanaka Y., Okada Y., Takeda S. Nodal flow and the generation of left-right asymmetry. Cell 2006, 125(1):33-45.
49. Boettger T., Wittler L., Kessel M. FGF8 functions in the specification of the right body side of the chick. Curr Biol 1999, 9(5):277-280.
50. Sun X., Meyers E.N., Lewandoski M., Martin G.R. Targeted disruption of Fgf8 causes failure of cell migration in the gastrulating mouse embryo. Genes Dev 1999, 13(14):1834-1846.
51. Bonetti M., Paardekooper Overman J., Tessadori F., Noel E., Bakkers J., den Hertog J. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish. Development 2014, 141(9):1961-1970.
52. Kreiling J.A., Balantac Z.L., Crawford A.R., Ren Y., Toure J., Zchut S., et al. Suppression of the endoplasmic reticulum calcium pump during zebrafish gastrulation affects left-right asymmetry of the heart and brain. Mech Dev 2008, 125(5-6):396-410.
53. Yoshiba S., Shiratori H., Kuo I.Y., Kawasumi A., Shinohara K., Nonaka S., et al. Cilia at the node of mouse embryos sense fluid flow for left-right determination via Pkd2. Science 2012, 338(6104):226-231.
54. Saund R.S., Kanai-Azuma M., Kanai Y., Kim I., Lucero M.T., Saijoh Y. Gut endoderm is involved in the transfer of left-right asymmetry from the node to the lateral plate mesoderm in the mouse embryo. Development 2012, 139(13):2426-2435.
55. i transient, and APD increase in cardiomyocytes. J Mol Cell Cardiol 2007, 43(6):710-716.
56. 2+ signaling. J Biol Chem 2006, 281(41):31093-31105.
57. Noel E.S., Verhoeven M., Lagendijk A.K., Tessadori F., Smith K., Choorapoikayil S., et al. A Nodal-independent and tissue-intrinsic mechanism controls heart-looping chirality. Nat Commun 2013, 4:2754.
58. Langdon Y., Tandon P., Paden E., Duddy J., Taylor J.M., Conlon F.L. SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton. Development 2012, 139(5):948-957.
59. Kathiriya I.S., Srivastava D. Left-right asymmetry and cardiac looping: implications for cardiac development and congenital heart disease. Am J Med Genet 2000, 97(4):271-279.
60. Franco D., Campione M. The role of Pitx2 during cardiac development Linking left-right signaling and congenital heart diseases. Trends Cardiovasc Med 2003, 13(4):157-163.
61. Lin C.J., Lin C.Y., Chen C.H., Zhou B., Chang C.P. Partitioning the heart: mechanisms of cardiac septation and valve development. Development 2012, 139(18):3277-3299.
62. de Lange F.J., Moorman A.F., Anderson R.H., Manner J., Soufan A.T., de Gier-de Vries C., et al. Lineage and morphogenetic analysis of the cardiac valves. Circ Res 2004, 95(6):645-654.
63. Wessels A., van den Hoff M.J., Adamo R.F., Phelps A.L., Lockhart M.M., Sauls K., et al. Epicardially derived fibroblasts preferentially contribute to the parietal leaflets of the atrioventricular valves in the murine heart. Dev Biol 2012, 366(2):111-124.
64. Abdelwahid E., Pelliniemi L.J., Jokinen E. Cell death and differentiation in the development of the endocardial cushion of the embryonic heart. Microsc Res Tech 2002, 58(5):395-403.
65. Armstrong E.J., Bischoff J. Heart valve development: endothelial cell signaling and differentiation. Circ Res 2004, 95(5):459-470.
66. Combs M.D., Yutzey K.E. Heart valve development: regulatory networks in development and disease. Circ Res 2009, 105(5):408-421.
67. Person A.D., Klewer S.E., Runyan R.B. Cell biology of cardiac cushion development. Int Rev Cytol 2005, 243:287-335.
68. Chen B., Bronson R.T., Klaman L.D., Hampton T.G., Wang J.F., Green P.J., et al. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet 2000, 24(3):296-299.
69. Araki T., Chan G., Newbigging S., Morikawa L., Bronson R.T., Neel B.G. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci USA 2009, 106(12):4736-4741.
70. Johnson E.N., Lee Y.M., Sander T.L., Rabkin E., Schoen F.J., Kaushal S., et al. NFATc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial cells. J Biol Chem 2003, 278(3):1686-1692.
71. Uhlen P., Burch P.M., Zito C.I., Estrada M., Ehrlich B.E., Bennett A.M. Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling. Proc Natl Acad Sci USA 2006, 103(7):2160-2165.
72. Ivins Zito C., Kontaridis M.I., Fornaro M., Feng G.S., Bennett A.M. SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis. J Cell Physiol 2004, 199(2):227-236.
73. Krenz M., Gulick J., Osinska H.E., Colbert M.C., Molkentin J.D., Robbins J. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome. Proc Natl Acad Sci USA 2008, 105(48):18930-18935.
74. Nakamura T., Colbert M., Krenz M., Molkentin J.D., Hahn H.S., Dorn G.W., et al. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest 2007, 117(8):2123-2132.
75. Nakamura T., Gulick J., Colbert M.C., Robbins J. Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development. Proc Natl Acad Sci USA 2009, 106(27):11270-11275.
76. Anderson R.H., Webb S., Brown N.A., Lamers W., Moorman A. Development of the heart: (2) Septation of the atriums and ventricles. Heart 2003, 89(8):949-958.
77. Wagner M., Siddiqui M.A. Signal transduction in early heart development (II): ventricular chamber specification, trabeculation, and heart valve formation. Exp Biol Med (Maywood) 2007, 232(7):866-880.
78. Tian Y., Morrisey E.E. Importance of myocyte-nonmyocyte interactions in cardiac development and disease. Circ Res 2012, 110(7):1023-1034.
79. Grego-Bessa J., Luna-Zurita L., del Monte G., Bolos V., Melgar P., Arandilla A., et al. Notch signaling is essential for ventricular chamber development. Dev Cell 2007, 12(3):415-429.
80. Zhang Y., Li S., Yuan L., Tian Y., Weidenfeld J., Yang J., et al. Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. Genes Dev 2010, 24(16):1746-1757.
81. Odiete O., Hill M.F., Sawyer D.B. Neuregulin in cardiovascular development and disease. Circ Res 2012, 111(10):1376-1385.
82. Sucov H.M., Dyson E., Gumeringer C.L., Price J., Chien K.R., Evans R.M. RXR alpha mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev 1994, 8(9):1007-1018.
83. Paardekooper Overman J., Yi J.S., Bonetti M., Soulsby M., Preisinger C., Stokes M.P., et al. PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice. Mol Cell Biol 2014, 34(15):2874-2889.
84. Roubelakis M.G., Martin-Rendon E., Tsaknakis G., Stavropoulos A., Watt S.M. The murine ortholog of the SHP-2 binding molecule PZR accelerates cell migration on fibronectin and is expressed in early embryo formation. J Cell Biochem 2007, 102(4):955-969.
85. Walter A.O., Peng Z.Y., Cartwright C.A. The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism. Oncogene 1999, 18(11):1911-1920.